Oppenheimer Initiates Outperform Coverage on Connect Biopharma with $8 Target, Implies 3.6x Upside
Rademikibart’s rapid action in acute asthma & COPD positions it for major upside ahead of Phase 2 readouts.
/ 5 items
#CNTB↓
Rademikibart Breakthrough Potential: Piper Sandler Sees First-in-Class Opportunity at CNTB
Rademikibart offers first-mover potential in acute asthma & COPD with major Phase 2 data coming in September 2026.
AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
Connect Biopharma Insider Buying: Panacea Venture Adds 1.16M Shares
Director James Huang and Panacea Venture bought 1.16 million shares of Connect Biopharma at $3.45, boosting their stake to 21.2%.
Roth Capital and BTIG Initiate Coverage on HeartBeam and Connect Biopharma with Buy Ratings
Roth Capital starts coverage on HeartBeam (BEAT) with a $4 target, while BTIG initiates on Connect Biopharma (CNTB) with a $10 target. Both firms see strong growth potential in innovative healthcare technologies.